Background: The choice between disease-modifying drugs (DMDs) for the treatment
| INTRODUCTION
Multiple sclerosis (MS) is a degenerative disease of the central nervous system causing physical and cognitive disabilities. 1 The relapsingremitting form of MS (RRMS) can be treated with disease-modifying drugs (DMDs) to reduce progression or even induce improvements.
DMD treatment requires long-term administration with a minimum of missed doses. DMDs are classified as first-, second-or third-line treatments. First-line DMDs are used in patients with mild disease activity. In case of high disease activity or intolerance to the side effects, second-or third-line DMDs may be chosen. These DMDs have more favourable effectiveness rates but less favourable safety profiles. 2, 3 Overall, thirteen DMDs are currently approved by the European Medicine Agency and the Food and Drug Administration. 4, 5 This variety in DMDs often provides MS patients with more than one acceptable option for treatment.
Therefore, a choice between DMDs needs to be made, which is often difficult. Besides differences in effectiveness rates and safety profiles, the DMDs can differ in other characteristics, or attributes, such as mode of administration and side effects. To make an optimal choice, the patient's preferences for such attributes should be incorporated in the decision. In shared decision making, the patient makes the decision about the treatment together with the healthcare professional. 6 The healthcare professional ensures the patient is informed about the best available treatment options and supports the patient in clarifying the advantages and disadvantages of each of the options.
The patient communicates his or her values and preferences for these advantages and disadvantages, and deliberates with the healthcare professional, in this case a neurologist and/or an MS nurse, about the treatment options to reach a decision. Decision aids, which are specifically designed to support shared decision making, have been shown to improve the patients' involvement in the decision and the quality of the decision. 7 Understanding the preferences of patients and healthcare professionals for treatment options could inform the development of a decision aid. Although the treatment decision should be individualized to every patient and should include the patient's preferences and healthcare professional's opinion tailored to the patient's needs, the evaluation of the average perspectives about the importance of the treatment attributes in the decision could be useful for developing a patient decision aid that meets most patients' and healthcare professionals' informational needs. An assessment of the average preferences could be valuable for selecting the information that needs to be included in the decision aid to ensure effectively supporting the shared decision-making process without making the use of the decision aid too cognitively burdensome for the patient. Preferences of patients for attributes of DMDs have been evaluated in several stated preference studies. [8] [9] [10] [11] [12] [13] [14] [15] [16] Recently, focus groups and a best-worst scaling were conducted to identify and prioritize a range of attributes that could be important in clinical decision making from the patients' perspective. 8 This study found that the average MS patient regarded the effects on disability progression and quality of life as the most important attributes of DMDs in the decision, followed by the effect on the relapse rate, severity of side effects and the effect on the severity of relapses. 8 Several studies showed that preferences of healthcare professionals for treatment options can differ from the preferences of patients. [17] [18] [19] [20] [21] These differences in preferences could result in different expectations and information needed from the decision aid. In MS, one study has assessed the neurologists' perspective regarding the importance of a limited number of five attributes in the DMD choice. 22 To our knowledge, the patients' perspective on important DMD attributes for choosing between DMDs has not yet been directly compared with the healthcare professionals' perspective.
This study aimed first to use a rigorous method, a best-worst scaling, to identify which DMD attributes the healthcare professionals (neurologists and MS nurses) find important to take into consideration in the decision regarding DMD treatment. As the relationship with the patient may differ between neurologists and MS nurses because of the more frequent and informal contact between MS nurses and patients, the second aim of this study was to evaluate whether the perspectives on the importance of DMD attributes differ between neurologists and MS nurses. Third, the overall MS healthcare professionals' (neurologists and MS nurses) perspective was compared with the MS patients'
perspective on the importance of DMD attributes in the treatment decision.
| METHODS
A best-worst scaling case 1 as described by Flynn and Marley 23 was conducted to obtain the neurologists' and MS nurses' perspective on the importance of attributes of DMDs. In contrast to discrete choice experiments, a best-worst scaling allows for obtaining the relative importance of attributes for a large number of attributes, regardless of the levels of the attributes. 24 The best-worst scaling was embedded
Key points
• Understanding the healthcare professionals' perspective about the importance of attributes of disease modifying drugs for multiple sclerosis, and comparing this perspective with the patients' perspective, would be important to develop a patient decision aid that is accepted by, and usable for, both patients and healthcare professionals in the shared decision-making process
• The healthcare professionals and patients overall agree about the importance of the effects of DMDs on disability progression, quality of life and relapse rate, but safety was valued significantly lower by patients.
• The study results provide guidance for the selection of information to be included in a patient decision aid for disease-modifying drugs in multiple sclerosis to effectively support the patient and healthcare professional in making a shared decision.
in an online questionnaire. Therefore, the Checklist for Reporting
Results of Internet E-Surveys was followed for reporting the design and the results. 25 We used the same best-worst scaling that was performed to elicit preferences for patients with MS. 8 The best-worst scaling included 27 attributes, which were identified in a two-stage Each attribute was presented 12 or 13 times in the four best-worst scaling version, was combined at least once with every other attribute and appeared two to four times in each position in the choice task.
Each respondent randomly received one of the best-worst scaling versions. In every choice task, the respondent was asked to state which attributes were the most and the least important in the decision about DMDs, making a hypothetical trade-off between the attributes.
24
The best-worst scaling was pilot tested among researchers (n=3) and patients with MS (n=3) to ensure comprehensibility of the question-
naire. An example of a choice task for neurologists and MS nurses is presented in Figure 1 . Further description on the identification, selection and definition of attributes and on the development of the choice tasks and the questionnaire is described in detail elsewhere. 8 In addition to the best-worst scaling choice tasks, questions about demographical and professional characteristics were included.
The respondents had to answer all questions to complete the questionnaire. At the end of the questionnaire, an optional open question provided the respondents the opportunity to report any important attributes in the decision about DMD treatment they missed in the choice tasks of the best-worst scaling.
| Subjects
Healthcare professionals were eligible for participation in the study Additionally, all nurse practitioners and physician assistants in MS (N=15) were also contacted through a mailing list of their professional association. In case of no response among the neurologists and nurses, a reminder email was sent after 1 and 2 weeks after the first email.
The neurologists and nurses were informed that by completing the questionnaire they gave consent for their responses to be used in the study. Cookies were used to prevent the same respondent from filling out the questionnaire twice. The study was fully anonymous, and no data, such as IP addresses, were recorded that could lead to the identity of the healthcare professional. F I G U R E 1 Example of a choice task in the best-worst scaling
| Analyses
Only completed questionnaires were included in the analyses.
Descriptive statistics were used to present characteristics of the neurologists and MS nurses. To evaluate the preferences of the healthcare professionals for the DMD attributes, Sawtooth SSI Web version 8.2.0 was used to perform a hierarchical Bayes model employing a multinomial logit procedure. 26 A raw score for the importance of each attribute was calculated in an iterative process of estimating each respondent's utility score conditionally on estimates of other respondents' utility scores. The raw score was rescaled to a relative importance score (RIS) on a ratio scale. 27 The RIS of an attribute repre- To assess whether the RISs assigned by the neurologists and nurses to the 27 attributes differed from the RISs assigned by the patients with MS, hierarchical Bayes analyses were conducted including responses of the neurologists and nurses, and responses of patients obtained in a previous study. 8 A second linear regression model was built to control for age, sex and level of education in the function between the respondent type (i.e. healthcare professional or patient) and the RISs of the 27 attributes. Level of education was dichotomized into respondents who had completed primary and/or secondary school only and respondents who had completed any additional type of tertiary education. The patients' perspective was obtained from a previous study among 185 patients with relapsing-remitting MS or clinically isolated syndrome, and with a range in experience with DMDs (from having never used a DMD to having used more than three different DMDs) and duration of diagnosis. Further detailed description of the patient recruitment and the patients characteristics can be found elsewhere. 
| Comparison of neurologists with MS nurses
Only few differences were found between neurologists and nurses (Table 2) . When comparing neurologists to nurses, relatively large differences in mean RISs (absolute difference in RISs of 1 or more)
were found in effect on current MS symptoms, effect on life expectancy and total costs of the DMD, which were higher for the neurologists, and interaction with other medication, which was higher for nurses. However, when controlling for sex, the years of work experience, the number of patients with MS treated each year and the degree of focus on MS treatment, only a significant difference was found between neurologists and nurses in the low ranked attributes total cost of the DMD (b=−1.27, P=.015) and interaction with other medication (b=2.09, P=.007). These differences resulted in quite substantial shifts in ranking: total cost of the DMD was ranked 17th by neurologists (RIS=1.22) and 25th by nurses (RIS=0.16), and interaction with other medication was ranked 18th by neurologists (RIS=1.10) and 13th by nurses (RIS=2.97). Based on their RISs though, these attributes did not influence the treatment decision severely.
| Comparison of healthcare professionals (neurologists and MS nurses) with patients
When controlling for age, sex and level of education, there were significant differences found between the RISs of the healthcare professionals and the patients with MS for six attributes at an alpha of .05:
effect on relapse rate and safety were more important for neurologists and nurses, while effect on current MS symptoms, pace of effect, insurance coverage and further development of the DMD were more important for the patients in the decision about DMDs. Furthermore, while the difference in RIS of 1.01 between the health care professionals and patients for influence on lifestyle was quite substantial, this difference was not significant when controlling for age, sex and level of education (P=.063). For safety, the difference was the most notable: the RIS for patients was substantially lower than for neurologists and nurses (b=−2.59, P<.001), making safety the fourth most important attribute for neurologists and nurses, and only the eighth most important attribute for patients. Table 3 
| DISCUSSION
In this study, a best-worst scaling was used to assess the neurologists'
and MS nurses' perspectives on the importance of 27 DMD attributes in the decision about DMD treatments, which enabled comparison of the healthcare professionals' perspective to the patients' perspective.
A best-worst scaling is a rigorous method for assessing preferences often used in healthcare research, 29 but, to our knowledge, has not been used before to prioritize the information about treatment options for the development of a decision aid. 
T A B L E 1 Characteristics of the health care professionals
This study found that neurologists and MS nurses ranked safety, effect on disability progression, effect on quality of life and effect on relapse rate highest. These attributes were thus considered as most influential in the decision making. Next in ranking were attributes focused on other effects and on side effects. Influence on lifestyle was the highest ranked (10th) attribute not directly related to benefits and possible harms but was only awarded a mean RIS of almost half of the most important attribute. One other study has evaluated the neurologists' perspective on important attributes in decisions about DMD by asking neurologists in the United States to rank five attributes. This study found, similarly to the current study, that efficacy and safety were the most important attributes, followed by tolerability, patient preferences and, lastly, convenience. 22 Within the group of healthcare professionals, we expected some differences in importance of attributes between neurologists and nurses as a result of a difference in the relationship with the patient. However, in our study we found only statistical differences in two low ranked attributes, suggesting that neurologists and MS nurses do not differ much in their perspective about what to consider in the decision about DMDs. The healthcare professionals and the patients both valued effect on disease progression, quality of life and relapse rate highly, which is not unexpected because these are the primary aims of DMD treatment. The most notable difference between the two perspectives was found in the importance of safety. The healthcare professionals gave significantly more value to this attribute compared with patients. More specifically, safety was ranked as fourth most important by healthcare professionals, while ranked only eighth by patients, who gave more value to other attributes focused on effectiveness and the severity of more common side effects. In the process of shared decision making, this could be an issue. Healthcare professionals may, for example, be less inclined than patients to choose a DMD for which experience and research has shown risks for life-threatening or severely disabling side effects, such as progressive multifocal leukoencephalopathy.
T A B L E 2 Relative importance scores of the DMD attributes in the treatment decision according to neurologists and nurses, and results of the multivariable analyses for work function (neurologist or nurse) while controlling for other variables
T Motivations of patients, neurologists and nurses for the importance of the attributes were not elicited in the questionnaire; therefore, we can only speculate about the reasons for the difference found in the importance of the attributes, in particularly safety. A first explanation for the difference in the importance of safety might be that healthcare professionals have a different understanding of the seriousness of the risks and consequences than patients. Second, patients might be willing to take more risk, as a previous study showed that patients were willing to accept larger risks than the risks associated with the DMDs available at that time, in exchange for effectiveness in reducing relapse rate and disability progression. 9 Healthcare professionals may be less inclined to take these risks, for example, because of forensic and legal liability in case of incidents of serious adverse events.
This study shows which attributes are most important in the decision, and that the rankings of the attributes are overall quite similar for neurologists, MS nurses and MS patients, with the exception of a few attributes-especially safety. It should be noted that the rankings reflect the average preferences. Therefore, the discrepancies do not necessarily play a role in every consultation. However, incorporating the patient's preferences in the decision is an essential part of reaching a shared decision, which may be complicated if the healthcare professional and patient do not agree on the importance of some attributes in the decision. Patient decision aids can, besides provide information, also support the patient and the healthcare professional in eliciting and discussing the patient's preferences. 30 The results of this study contribute to the development of an MS decision aid by indicating the attributes-those attributes that both patients and healthcare professionals find most important and those attributes that are substantially more important for either patients or healthcare professionals-about which information and preference elicitation questions should be in- Other limitations that apply to the best-worst scaling method and the results of the patients' perspective have been reported elsewhere. 
| CONCLUSION
This study showed that safety, effect on disability progression and effect on quality of life were the most influential attributes of DMDs for healthcare professionals in the treatment decision. The importance of these and other highly ranked attributes did not differ between neurologists and nurses when making a decision for patients with MS in general. Additionally, the average healthcare professionals' perspective and the average patients' perspective agree that the ability of DMDs to reduce disability progression and maintain or improve quality of life are the most important attributes of a DMD. The perspectives differ however considerably about the importance of safety.
These results provide valuable information for the development of interventions to support shared decision making. This study also demonstrates the feasibility of combining focus groups and a best-worst scaling to identify important attributes that could later be included in a patient decision aid. A best-worst scaling could be an interesting method when having to restrict the number of attributes for inclusion in a patient decision aid.
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